Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
In this cohort study of individuals with RA and new biologic or targeted synthetic DMARD exposures, individuals initiating rituximab, abatacept, and JAKis demonstrated higher incidence rates and statistically significantly increased risks of incident cancers compared with those initiating TNFis in the first 2 years after initiation of biologic or targeted synthetic DMARDs. Given the limitations of administrative claims data and confounding by indication, it is likely that these patients may have a higher disease burden, resulting in channeling bias. To better understand these associations, larger studies with longer follow-up time are needed.
Authors
- Mathilde H. Pioro
- Jeffrey A. Sparks (ORCID: https://orcid.org/0000-0002-5556-4618)
- James S. Andrews (ORCID: https://orcid.org/0000-0003-2302-4358)
- Radjiv Goulabchand (ORCID: https://orcid.org/0000-0002-7328-4097)
- Laura S. Gold (ORCID: https://orcid.org/0000-0002-4289-5231)
- Maureen Dubreuil (ORCID: https://orcid.org/0000-0002-6253-1515)
- David Liew (ORCID: https://orcid.org/0000-0001-8451-8883)
- Jeffrey G. Jarvik (ORCID: https://orcid.org/0000-0002-0528-3455)
- Pankti Reid (ORCID: https://orcid.org/0000-0002-7645-0919)
- Jean W. Liew (ORCID: https://orcid.org/0000-0002-8104-2450)
- Xavier Sendaydiego
- Grant C. Hughes (ORCID: https://orcid.org/0000-0003-1856-2493)
- Abha G. Singh
- Siddharth Singh
- Namrata Singh
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Inserm (FR)
- The University of Melbourne (AU)
- Université de Montpellier (FR)
- University of Washington (US)
- VA Boston Healthcare System (US)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- University of Chicago Medical Center (US)
- Geriatric Research Education and Clinical Center (US)
- Washington Center (US)
- Austin Health (AU)
- Université de Nîmes (FR)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.46336
- Citations
- 7
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.29
Funders
- George Gund Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Rheumatology Research Foundation
- University of Washington
- Australian Government
- National Institutes of Health